Cellectar Bioscience (CLRB)
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of ca...
- Open
- 2.600
- High
- 2.600
- Low
- 2.500
- Prev. Close
- 2.590
- Volume
- 26.65K
- Turnover
- 68.57K
- Avg Price
- 2.573
- Bid/Ask Ratio
- --
- Amplitude
- 3.86%
- 52wk High
- 6.520
- Volume Ratio
- 0.87
- Turnover Ratio
- 0.36%
Cellectar Bioscience Analyst Rating
View moreForecast & Rating
Aug 18, 2026Price forecast
$11.50344.02%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Motley Fool · 1 day ago, 08:56 AM
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
- PUBT · Aug 18 at 02:24 PM
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program
- Quartr · Aug 18 at 02:20 PM
CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials
- Tip Ranks · Aug 14 at 11:55 AM
Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated
- TradingKey · Aug 14 at 03:12 AM
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call: Phase III Startup and 2027 NDA Plan
- benzinga_article · Aug 13 at 08:19 AM
Cellectar Biosciences Q2 2026 Earnings Call Transcript
